Health Effects of Overweight and Obesity in 195 Countries over 25 Years.
- Ashkan Mohammad H. Marissa Patrick Kara Alex Laurie Ali H Afshin Forouzanfar Reitsma Sur Estep Lee Marczak M, A. Afshin, C. Murray
- MedicineNew England Journal of Medicine
- 12 June 2017
The rapid increase in the prevalence and disease burden of elevated BMI highlights the need for continued focus on surveillance of BMI and identification, implementation, and evaluation of evidence‐based interventions to address this problem.
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global…
- M. Forouzanfar, A. Afshin, C. Murray
- MedicineThe Lancet
- 5 December 2015
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015
- Haidong Wang, M. Naghavi, C. Murray
- MedicineThe Lancet
- 8 October 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
- E. Simpson, T. Bieber, M. Ardeleanu
- MedicineNew England Journal of Medicine
- 30 September 2016
Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study.
- J. Silverberg, J. Hanifin
- MedicineJournal of Allergy and Clinical Immunology
- 1 November 2013
Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of…
- N. Kassebaum, Megha Arora, C. Murray
- MedicineThe Lancet
- 8 October 2016
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- E. Simpson, J. Lacour, K. Reich
- Medicine, BiologyBritish Journal of Dermatology
- 29 January 2020
Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids.
Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): A systematic review.
- B. Adler, A. Krausz, Aurelia Minuti, J. Silverberg, H. Lev-Tov
- MedicineJournal of American Academy of Dermatology
- 1 March 2016
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
- J. Silverberg, E. Simpson, R. Rojo
- MedicineJAMA dermatology
- 3 June 2020
Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD) and laboratory values indicating thrombocytopenia.
Baricitinib in adult patients with moderate‐to‐severe atopic dermatitis: A phase 2 parallel, double‐blinded, randomized placebo‐controlled multiple‐dose study
- E. Guttman-Yassky, J. Silverberg, E. Simpson
- MedicineJournal of American Academy of Dermatology
- 2 February 2018
...
...